1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow Facioscapulohumeral Muscular Dystrophy (FSHD): new trials by email Literature Review of Facioscapulohumeral Muscular Dystrophy (FSHD) trials Research Report on Facioscapulohumeral Muscular Dystrophy (FSHD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH) Losmapimod, Placebo oral tablet - Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 3 | Terminated | Fulcrum Therapeutics | 260 | 2022-06-16 | 2025-11-10 |
Muscular Dystrophies (1) · Muscular Dystrophy, Facioscapulohumeral (1) · Musculoskeletal Diseases (1) · Neuromuscular Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Muscular Diseases (1) · Muscular Disorders, Atrophic (1) · Nervous System Diseases (1)
Canada (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1) · United Kingdom (1) · United States (1)